Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Price:
10.24 USD
-5.54%
Market Closed
Updated:
May 8, 2024
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to FCFF
-4.7
Current
-4
Median
17.8
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
EV/FCFF
=-4.7
Enterprise Value
/
649.7m
FCFF
-139.2m
All Countries
| Market Cap | EV/FCFF | ||||
|---|---|---|---|---|---|
| US |
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
593.4m USD | -4.7 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -15 979 072.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
739.2B USD | -195.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 78.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 13 236.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.9B USD | 19.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.2B USD | 32.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.8B GBP | 414.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
175.7B CHF | 19.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.4B CHF | 36.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 44.6 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A
You don't have any saved screeners yet
